Publications by authors named "Line Hammer Dohn"

Claim this Profile
A
Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma.
Dag Rune Stormoen, Signe Lehn, Kent W Mouw, Zoltan Szallasi, Linea Cecilie Melchior, Line Hammer Dohn

Sci Rep· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DaBlaCa-17: nationwide observational study in Denmark on survival before and after implementation of neoadjuvant chemotherapy prior to cystectomy for muscle-invasive bladder cancer.
Stefanie Korsgaard Körner, Thomas Dreyer, Andreas Carus, Line Hammer Dohn, Ulla Nordström Joensen

Scand J Urol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The iBLAD study: patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial.
Gry Assam Taarnhøj, Christoffer Johansen, Andreas Carus, Rikke Hedegaard Dahlrot, Line Hammer Dohn

J Patient Rep Outcomes· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The iBLAD app protocol - a national, exploratory study on a multimodality smartphone app in bladder cancer for better understanding symptoms, quality of life and need for supportive care.
Lærke Kjær Tolstrup, Anne Birgitte Als, Andreas Carus, Rikke Dahlrot, Line Hammer Dohn

Acta Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Implications for Efficacy and Safety of Total Dose and Dose-Intensity of Neoadjuvant Gemcitabine-Cisplatin in Muscle-Invasive Bladder Cancer: Three-Week Versus Four-Week Regimen.
Karin Holmsten, Lise Høj Omland, Anne Birgitte Als, Mads Agerbæk, Line Hammer Dohn

Bladder Cancer· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Study of Treatment with Pembrolizumab Among Patients with Advanced Urothelial Tract Cancer in Denmark.
Lise Høj Omland, Dag Rune Stormoen, Line Hammer Dohn, Andreas Carus, Anne Birgitte Als

Bladder Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Status of Metastatic Bladder Cancer Treatment Illustrated by a Case.
Line Hammer Dohn, Lise Høj Omland, Dag Rune Stormoen, Helle Pappot

Semin Oncol Nurs· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy - a feasibility study.
Gry Assam Taarnhøj, Henriette Lindberg, Line Hammer Dohn, Lise Høj Omland, Niels Henrik Hjøllund

Health Qual Life Outcomes· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An updated review on primary signet-ring cell carcinoma of the urinary bladder and report of a case.
Maria Elisabeth Lendorf, Line Hammer Dohn, Bara Á Dunga, Anand C Loya, Helle Pappot

Scand J Urol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
uPAR Expression Pattern in Patients with Urothelial Carcinoma of the Bladder--Possible Clinical Implications.
Line Hammer Dohn, Helle Pappot, Benedikte Richter Iversen, Martin Illemann, Gunilla Høyer-Hansen

PLoS One· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.
Christina H Ruhlmann, Thomas Broe Christensen, Line Hammer Dohn, Merete Paludan, Eva Rønnengart

Lancet Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder.
Line Hammer Dohn, Martin Illemann, Gunilla Høyer-Hansen, Ib J Christensen, Jens Hostmark

Urol Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis